The Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the adult population of developed countries and has been
widely associated with the metabolic syndrome and increased cardiovascular risk. The pathogenesis of NAFLD remains
unclear and its pharmacological treatment undefined. The activation of the renin?angiotensin system appears to be involved in
the pathological process of NAFLD. Experimental models have suggested that angiotensin II plays an important role in oxidative
stress, inflammatory response and hepatic fibrogenesis. Also, the relationship between the activation of the renin?angiotensin
system and insulin resistance has been shown experimentally. Furthermore, results of experiments using angiotensin II receptor
blockers suggest positive effects of this therapeutic class in NAFLD. We conducted these studies to assess if candesartan, telmisartan
and olmesartan, AT1 receptor blockers have preventive action on NAFLD in hypercholesterolemic rabbits. In these studies, the
three drugs significantly attenuated hepatic steatosis and olmesartan prevented the development of lobular inflammation and
liver fibrosis. The NAFLD activity score was significantly lower in olmesartan group compared to control group.
M?rio Cl?udio Soares Sturzeneker, has completed the master's course at the Pontif?cia Universidade Cat?lica do Paran?, Brazil. He is currently an
Assistant Professor at the State University of Ponta Grossa.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals